Der forventes ingen klinisk signifikante interaktioner, da NRTIer metaboliseres ad en anden vej end efavirenz, og det vil være usandsynligt, at disse vil konkurrere om de samme metaboliseringsenzymer og eliminationsveje.
Clinically significant interactions are not expected since the NRTIs are metabolised via a different route than efavirenz and would be unlikely to compete for the same metabolic enzymes and elimination pathways.